Navigation Links
Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
Date:1/10/2011

CAMBRIDGE, Mass. and NEW YORK, Jan. 10, 2011 /PRNewswire/ -- Resolvyx Pharmaceuticals (Resolvyx) and Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, announced today that they have entered into a final agreement under which Celtic Therapeutics has acquired and licensed worldwide rights related to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.  Terms of the deal include upfront consideration, near-term milestone payments, and funding for 100% of future development costs. Resolvyx and Celtic Therapeutics will share proceeds from the future divestiture of RX-10045, including up-front payments, royalties or other revenues.

Under the terms of the agreement, Celtic Therapeutics will acquire and license rights to Resolvyx's RX-10045, in all ophthalmic indications. RX-10045 is scheduled to enter a Phase III randomized, placebo-controlled, multi-center study in 2011. As part of the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. Resolvins are shown to be highly potent and efficacious across a broad range of pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx will continue to develop Resolvins for non-ophthalmic indications.

Dry eye, one of the most common problems treated by ophthalmologists, and a $1.7 billion global market today, is a chronic, multifactorial disease involving inflammation of the tear ducts and ocular surfaces that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surfaces. RX-10045, a resolvin
'/>"/>

SOURCE Celtic Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  SynCardia Systems, Inc. has received FDA approval to ... the effective use of its 50cc SynCardia temporary Total ... The FDA approval will allow SynCardia to launch ... patients. Patients enrolled in this study will receive the ... a donor heart transplant. (Caution-In the United States, ...
(Date:3/31/2015)... 2015 PGI has announced an expansion of ... America at its San Luis ... plant expansion is centered on solving the challenge of ... for personal care product manufacturers. The ... slitting and packaging, will allow customers to take advantage ...
(Date:3/31/2015)... 31, 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: ... that specializes in developing safer, more effective cannabis-based ... C. Anderson , Ph.D., to its Scientific Advisory ... who brings significant drug discovery and development expertise ... synthetic organic chemist by training with more than ...
Breaking Medicine Technology:FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4PGI Expands Manufacturing Capabilities At Mexico Plant 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4
... -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET ... the development, manufacturing and marketing of traditional Tibetan ...  "In recent days, we noticed that a website ... were untrue and incorrect announcements. Our company is in ...
... N.J. Feb. 27, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: ... the three months ended December 31, 2011, which reflect ... KRYSTEXXA®(pegloticase). Savient ended the quarter with approximately $170 million ... million for the quarter. For the fourth quarter of ...
Cached Medicine Technology:Tibet Pharmaceuticals, Inc. Announces Intent to Go Private 2Tibet Pharmaceuticals, Inc. Announces Intent to Go Private 3Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 2Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 3Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 4Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 5Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 6Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 7
(Date:3/31/2015)... 31, 2015 OnChip Devices , a ... wire-bondable silicon ESD diode chip targeted towards low voltage LED ... these Zeners are ideal for protecting circuits by suppressing voltage ... can handle pulses of up to 350W and 20A, providing ... IEC 61000-4-2 standard. These diodes do not exhibit any ...
(Date:3/31/2015)... Los Angeles, CA (PRWEB) March 31, 2015 ... titled “Would You Go Down the Silicone Slope?” provides a ... , dermal filler , and laser treatments . ... an example) and reality TV stars such as Kim Kardashian ... and other social media are increasingly seen as significant influences ...
(Date:3/31/2015)... 31, 2015 Clinovo, a leading ... Membership Program , the premiere voice of Northern ... life science companies. , BayBio brings together ... most innovative and productive life science cluster, helping ... of humanity’s most pressing challenges. , “We ...
(Date:3/31/2015)... March 31, 2015 Dr. St. Ledger recently ... for Advanced Dental Education. Here, he participated in the ... to create a greater predictability in cases of severely worn ... of tooth wear, and the correlation to GERD and Sleep ... Mentor at Spear Education. After the workshop he attended, ...
(Date:3/31/2015)... At Summit Breast Care, their passion is to provide ... caring manner. , Summit Breast Care has achieved national recognition ... cancer. They treat thousands of patients annually, not just ... Their doctors continue to be recognized as ‘Top Doctors’ ... Breast Care were planted in the mind and spirit of ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Cosmetic Surgery: Does Social Media Pressure Young Girls to Get Botox and Fillers? 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:The dentists at Upper Montclair Dental Associates are happy to announce exciting new happenings at their practice. 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... and Eliza Hall Institute (WEHI) has contributed significantly ... biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, ... Licensing Agreement, Merck Serono will seek to develop ... autoimmune conditions. These prospective treatments will be based ...
... July 2 SuperGen, Inc.,(Nasdaq: SUPG ), ... and commercialization of therapies for solid tumors and,hematological ... and Chief Executive Officer, is scheduled to present ... 9, 2008 at the,Mandarin Oriental Hotel in New ...
... 2 The Female Health Company,(Amex: FHC ) ... Russell,Microcap(R) Index after the Russell Investment Group reconstituted its,comprehensive ... 27, 2008., The Russell Microcap(R) Index measures the ... the U.S. equity market. The Russell,Microcap(R) Index includes the ...
... Calif. and YOKOHAMA CITY, Japan, July 2 ... technology company,and Tokyo Electron Device Limited (TED), ... of inrevium evaluation board solutions, and,provider of ... the,distribution of Samplify,s patented Prism(TM) signal compression ...
... improved version of AmWay's MagnaBloc. , ... Memphis, TN ... pain management, is now available in a new, stronger form: ... released in the United States, and will be available worldwide within ...
Cached Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:MS drug development agreement based on WEHI's medicinal chemistry 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:The Female Health Company Added to Russell Microcap(R) Index 2Health News:The Female Health Company Added to Russell Microcap(R) Index 3Health News:The Female Health Company Added to Russell Microcap(R) Index 4Health News:Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology 2Health News:New MagnaBloc™ Product Available from Gradient Medical 2
... Projector Chart w/ Remote/Controller. Includes ... Adults & Children. Multiple 20/20 slides. ... Programmable feature allows you to customize your ... Halogen Illumination with Long Life. Variety of ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
... Inc., the leader in beating heart bypass, ... new Starfish NS device is the first ... patient acceptance of surgical revascularization.,The Starfish NS ... the Multi-Vessel Small Thoracotomy (MVST) procedure without ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
Medicine Products: